Valuation : Access Pharmaceuticals, Inc.

Market Cap 34Cr 29Cr 27Cr 25Cr 47Cr 3.2TCr 47Cr 324.42Cr 125.89Cr 1.64TCr 127.34Cr 124.56Cr 5.29TCr P/E 2026 *
-6.21x
P/E 2027 * -31.5x
Enterprise Value 34Cr 29Cr 27Cr 25Cr 47Cr 3.2TCr 47Cr 324.42Cr 125.89Cr 1.64TCr 127.34Cr 124.56Cr 5.29TCr EV / Sales 2026 *
6.24x
EV / Sales 2027 * 2.85x
Free-Float
79.59%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 50 15/10/2021
Director of Finance/CFO 42 14/03/2022
Chief Tech/Sci/R&D Officer - 20/10/2025
Director TitleAgeSince
Director/Board Member 58 01/03/2006
Director/Board Member 64 25/03/2021
Director/Board Member 63 19/04/2021
Change 5-day change 1-year change 3-year change Capi.($)
+0.26%+4.26%+45.98%+0.62% 8.42TCr
-0.57%+0.36%-15.55%-35.15% 6.05TCr
-2.51%+5.33%+498.60%+32.90% 5.94TCr
-2.03%-9.22%-7.00%+28.39% 5.03TCr
-4.58%-5.09%+4.26%+153.55% 4.89TCr
-1.58%+1.10%+57.85%-17.05% 3.32TCr
-0.94%+2.07%+48.57%+100.60% 2.59TCr
-0.19%-4.83%-4.30%+191.74% 2.28TCr
-1.13%-2.45%+65.99%+110.75% 1.67TCr
Average -1.49%+0.02%+77.16%+62.93% 4.47TCr
Weighted average by Cap. -1.46%+0.89%+91.07%+42.50%

Financials

2026 *2027 *
Net sales 5.43Cr 4.68Cr 4.4Cr 4.02Cr 7.52Cr 513.03Cr 7.54Cr 52Cr 20Cr 263.22Cr 20Cr 20Cr 847.98Cr 12Cr 10Cr 9.62Cr 8.79Cr 16Cr 1.12TCr 16Cr 113.72Cr 44Cr 575.79Cr 45Cr 44Cr 1.85TCr
Net income -5.45Cr -4.69Cr -4.41Cr -4.03Cr -7.54Cr -514.65Cr -7.56Cr -52Cr -20Cr -264.05Cr -20Cr -20Cr -850.64Cr -92.18L -79.33L -74.63L -68.18L -1.28Cr -87Cr -1.28Cr -8.82Cr -3.42Cr -45Cr -3.46Cr -3.39Cr -143.86Cr
Net Debt - -
Logo Access Pharmaceuticals, Inc.
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. The Company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa. Its fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. Its development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Its AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. Its pipeline programs include ABO-504 (Stargardt disease), ABO-503 (X-linked retinoschisis), ABO-505 (autosomal dominant optic atrophy), UX111 (Sanfilippo Syndrome Type A (MPS IIIA)), TSHA-102 (Rett Syndrome), and TSHA-118 (Infantile Batten Disease (CLN1 Disease)).
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-